RxSight, Inc. filings document the public-company record for a Nasdaq-listed ophthalmic medical device issuer centered on the RxSight Light Adjustable Lens system. Form 8-K reports furnish operating results, sales guidance, Light Adjustable Lens and Light Delivery Device commercial metrics, preliminary results and other material updates tied to financial condition.
The company’s proxy and governance filings cover annual meeting matters, board and committee composition, executive compensation, equity awards and stockholder voting procedures. Other current reports address officer appointments, transition agreements, compensatory arrangements and the registered common stock structure for RXST.
RxSight, Inc. reported Q2 2026 revenue of $33,741 (amounts in thousands of dollars), compared with $33,637 a year earlier. Product sales declined to $27,241, while license and collaboration revenue of $6,500 from a new Alcon agreement offset much of that change. Q2 net loss was $12,097, or $0.29 per share.
For the first six months of 2026, revenue was $64,634 and net loss $27,981, with operating cash outflows of $20,429 (all in thousands). Liquidity remained strong with $208.8 million in cash, cash equivalents and short‑term investments. RxSight ended June with 1,166 installed Light Delivery Devices and approximately 357,000 cumulative Light Adjustable Lens implants.
The Alcon collaboration includes a $60 million upfront payment, of which $10.0 million is the initial transaction price, with $6.5 million recognized as license revenue and $3.5 million deferred. The remaining $50.0 million is refundable within 120 days. Alcon may also owe $70 million, $30 million and $40 million milestones plus 30% royalties on Collaboration Product net sales.
RxSight, Inc. reported second-quarter 2026 revenue of $33.7 million, including $6.5 million from its strategic collaboration with Alcon and $27.2 million of product sales. Product sales declined 19% from a year earlier, reflecting competitive trialing and softer consumer sentiment, and included 24,917 Light Adjustable Lens units and 12 Light Delivery Devices.
Excluding collaboration revenue, gross margin was 71.2% versus 74.9% a year ago; including it, gross margin was 76.7%. Operating expenses were $39.7 million, and the company posted a net loss of $12.1 million, or $0.29 per share, with adjusted net loss of $4.6 million, or $0.11 per share. Cash, cash equivalents and short-term investments totaled $208.8 million as of June 30, 2026.
RxSight appointed Aziz Mottiwala as President and Chief Executive Officer, entered a strategic collaboration with Alcon featuring up to $200 million in potential upfront and milestone payments plus future royalties, and advanced next-generation Light Adjustable Lens technologies. In connection with the leadership transition, it withdrew 2026 guidance and plans to resume formal guidance in early 2027.
RxSight, Inc. is reported to have 3,030,287 shares of its common stock beneficially owned by Millennium Management LLC, Millennium Group Management LLC and Israel A. Englander, representing 7.3% of the class as of June 30, 2026. Each reporting person lists 0 shares with sole voting or dispositive power and 3,030,287 shares with shared voting and shared dispositive power. The securities are held by entities subject to voting control and investment discretion of Millennium Management LLC and/or other investment managers controlled by Millennium Group Management LLC and Mr. Englander, and the reporting persons state that this description should not by itself be construed as an admission of beneficial ownership. A Joint Filing Agreement dated August 3, 2026 is included as an exhibit.
RxSight, Inc. granted President and CEO Aziz Mottiwala 2,312,138 restricted stock units, each representing a contingent right to one share of Common Stock, and stock options for 571,286 shares at an exercise price of $5.19 per share. The RSUs and options vest over multi-year schedules contingent on continued service, with resulting direct holdings equal to the granted amounts.
RxSight, Inc. filed an initial Form 3 identifying Aziz Mottiwala as a reporting person in his roles as President and CEO and as a director. The filing does not list any equity holdings or transactions for him, and includes a reference to an Exhibit 24 Power of Attorney.
BlackRock Portfolio Management LLC reports a significant passive ownership position in RxSight, Inc. common stock. As of June 30, 2026, it beneficially owned 2,982,816 shares, representing 7.2% of the outstanding common stock.
BlackRock Portfolio Management LLC has sole voting power over 2,618,543 shares and sole dispositive power over 2,982,816 shares, with no shared voting or dispositive power. Various underlying clients have economic interests in these shares, but no individual client holds more than five percent of RxSight’s total outstanding common shares.
RxSight, Inc. announced a planned leadership transition effective July 20, 2026, appointing Aziz Mottiwala as President and Chief Executive Officer and a Class II director, while long-time CEO Ron Kurtz, M.D. becomes Chief Medical Officer and resigns from the board.
Mottiwala’s employment letter provides a $750,000 base salary, an annual bonus opportunity of up to 90% of base, a guaranteed $337,500 cash bonus for 2026, and new-hire equity awards valued at $14,000,000, split between stock options and RSUs with multi‑year vesting. A Change in Control Severance Agreement includes cash severance equal to 18 months of salary and target bonus, COBRA reimbursements and 100% equity vesting acceleration upon specified terminations and upon a change in control.
A transition agreement keeps Kurtz at a $740,000 base salary with up to 100% target bonus, four retention bonuses of $370,000 each, and 500,000 RSUs vesting through 2028, plus revised severance protections. The board also adopted a 2026 Inducement Equity Incentive Plan reserving 3,500,000 shares for new‑hire awards. Previously communicated financial guidance remains unchanged.
RxSight, Inc. announced preliminary second quarter 2026 results and updated its 2026 outlook following a strategic collaboration with Alcon. Q2 2026 total revenue is expected at $32 to $34 million, including $5 to $7 million from the Alcon collaboration. Product sales were about $27 million, driven by 24,917 Light Adjustable Lens units and 11 Light Delivery Devices, plus one rental placement. The company reported $209 million in cash, cash equivalents and short-term investments as of June 30, 2026. For full-year 2026, total revenue is guided to $140 to $160 million, with sales of $110 to $120 million, below prior sales guidance, and collaboration revenue of $30 to $40 million. RxSight now expects gross margin of 73% to 75%, above previous guidance, and operating expenses near the high end of $150 to $160 million, as it accelerates commercial and R&D investments.
RxSight, Inc. entered into a significant license, collaboration and development agreement with Alcon to co-develop and commercialize light-adjustable presbyopia-correcting intraocular lenses that combine RxSight’s Light Adjustable Technology with Alcon’s existing optics.
Alcon will pay RxSight a $60 million upfront cash payment, with an optional $70 million feasibility milestone if Alcon chooses to continue after early technical criteria are met. If the collaboration proceeds, Alcon would also pay a $30 million milestone upon first FDA submission and an optional $40 million approval milestone upon U.S. regulatory approval of the first product, plus ongoing 30% royalties on net sales of collaboration products, subject to minimums and adjustments.
RxSight will prioritize development, seek U.S. regulatory approvals and exclusively manufacture and supply the collaboration lenses, while Alcon will lead commercialization and has rights to terminate by declining key milestone payments. The agreement generally runs for ten years after first product approval, with renewal options and multiple termination and reversion provisions.
Warner Robert Keith reported acquisition or exercise transactions in this Form 4 filing.
RxSight, Inc. director Robert Keith Warner received an equity award of 37,037 restricted stock units (RSUs) of common stock as compensation. Each RSU represents one share of RxSight common stock, bringing his direct holdings to 78,076 shares following the grant.
The RSUs will vest in full if he continues as an Outside Director until the earlier of the one-year anniversary of the June 17, 2026 grant date or the next annual meeting of stockholders after that date. This is a non-cash award rather than an open-market share purchase.